Poseida Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q2 2019 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Poseida Therapeutics, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q2 2019 to Q3 2024.
  • Poseida Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2024 was $4.96M, a 3.09% decline year-over-year.
  • Poseida Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2024 was $23M, a 1.84% increase year-over-year.
  • Poseida Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $23.1M, a 22.2% increase from 2022.
  • Poseida Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $18.9M, a 13.3% increase from 2021.
  • Poseida Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $16.7M, a 131% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $23M $4.96M -$158K -3.09% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-07
Q2 2024 $23.2M $7.63M +$2.16M +39.4% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-05
Q1 2024 $21M $5.38M -$2.1M -28% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-14
Q4 2023 $23.1M $5.06M +$515K +11.3% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-07
Q3 2023 $22.6M $5.12M +$840K +19.6% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-07
Q2 2023 $21.8M $5.47M +$240K +4.59% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-05
Q1 2023 $21.5M $7.48M +$2.61M +53.7% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-14
Q4 2022 $18.9M $4.55M +$199K +4.58% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-07
Q3 2022 $18.7M $4.28M +$126K +3.04% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 $18.6M $5.23M +$492K +10.4% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 $18.1M $4.87M +$1.41M +40.6% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-09
Q4 2021 $16.7M $4.35M +$2.15M +97.7% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-09
Q3 2021 $14.6M $4.15M +$2.26M +119% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 $12.3M $4.74M +$3.13M +193% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-11
Q1 2021 $9.17M $3.46M +$1.95M +129% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
Q4 2020 $7.22M $2.2M Oct 1, 2020 Dec 31, 2020 10-K 2022-03-10
Q3 2020 $1.9M +$1.22M +180% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-09
Q2 2020 $1.62M +$1.01M +166% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-12
Q1 2020 $1.51M Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-11
Q3 2019 $676K Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-12
Q2 2019 $607K Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-20
* An asterisk sign (*) next to the value indicates that the value is likely invalid.